Adolescents and Young Adults With ALL

Source: Childhood Acute Lymphoblastic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 21, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Postinduction Treatment for Specific ALL Subgroups

Adolescents and young adults with ALL have been recognized as high risk for decades. Outcomes for this age group are inferior in almost all studies of treatment compared with children younger than 10 years.[42-44] The reasons for this difference include more frequent presentation of adverse prognostic factors at diagnosis, including the following:

Source links and citations

T-cell immunophenotype.

BCR::ABL1 and BCR::ABL1-like disease.

Lower incidence of favorable cytogenetic abnormalities.

In addition to more frequent adverse prognostic factors, patients in this age group have higher rates of treatment-related mortality [43-46] and nonadherence to therapy.[45,47]

Source links and citations

Continue within this section

Treatment options for adolescents and young adults with ALL →Treatment options under clinical evaluation for adolescent and young adult patients with ALL →

Publication references

Read the original reference and check its publication notices.

Preserved source evidence · Not medical advice